Nathanael S. Gray

84.8k total citations · 22 hit papers
476 papers, 42.2k citations indexed

About

Nathanael S. Gray is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Nathanael S. Gray has authored 476 papers receiving a total of 42.2k indexed citations (citations by other indexed papers that have themselves been cited), including 359 papers in Molecular Biology, 141 papers in Oncology and 72 papers in Hematology. Recurrent topics in Nathanael S. Gray's work include Protein Degradation and Inhibitors (123 papers), Ubiquitin and proteasome pathways (73 papers) and PI3K/AKT/mTOR signaling in cancer (44 papers). Nathanael S. Gray is often cited by papers focused on Protein Degradation and Inhibitors (123 papers), Ubiquitin and proteasome pathways (73 papers) and PI3K/AKT/mTOR signaling in cancer (44 papers). Nathanael S. Gray collaborates with scholars based in United States, United Kingdom and China. Nathanael S. Gray's co-authors include Jianming Zhang, Priscilla L. Yang, David M. Sabatini, Peter G. Schultz, Tinghu Zhang, Carson C. Thoreen, Yi Liu, Qingsong Liu, Seong A. Kang and Fleur M. Ferguson and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Nathanael S. Gray

466 papers receiving 41.5k citations

Hit Papers

Targeting cancer with small molecule kinase inhibitors 1998 2026 2007 2016 2008 2009 2012 2009 2000 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Targeting cancer with small molecule kinase inhibitors
    2008 2.0k citations Jianming Zhang, Nathanael S. Gray et al. profile →
  2. An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
    2009 1.4k citations Carson C. Thoreen, Seong A. Kang et al. profile →
  3. A unifying model for mTORC1-mediated regulation of mRNA translation
    2012 1.1k citations Carson C. Thoreen, Nathanael S. Gray et al. profile →
  4. DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival
    2009 950 citations Carson C. Thoreen, Seong A. Kang et al. profile →
  5. A chemical switch for inhibitor-sensitive alleles of any protein kinase
    2000 862 citations Nathanael S. Gray, Peter G. Schultz et al. profile →
  6. Rational design of inhibitors that bind to inactive kinase conformations
    2006 855 citations Nathanael S. Gray et al. profile →
  7. The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling
    2011 840 citations Seong A. Kang, Kathleen Ottina et al. Science profile →
  8. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
    2009 785 citations Wenjun Zhou, Marzia Capelletti et al. profile →
  9. Kinase inhibitors: the road ahead
    2018 691 citations Nathanael S. Gray et al. profile →
  10. Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors
    1998 676 citations Nathanael S. Gray, Peter G. Schultz et al. Science profile →
  11. YY1 Is a Structural Regulator of Enhancer-Promoter Loops
    2017 661 citations Behnam Nabet, Rudolf Jaenisch et al. profile →
  12. The dTAG system for immediate and target-specific protein degradation
    2018 652 citations Behnam Nabet, Jun Qi et al. profile →
  13. Sphingosine 1-Phosphate (S1P) Receptor Subtypes S1P1 and S1P3, Respectively, Regulate Lymphocyte Recirculation and Heart Rate
    2004 521 citations Nathanael S. Gray et al. profile →
  14. Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
    2013 513 citations Qingsong Liu, Nathanael S. Gray et al. profile →
  15. CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer
    2014 451 citations Kwok‐Kin Wong, Nathanael S. Gray et al. profile →
  16. Plasticity in binding confers selectivity in ligand-induced protein degradation
    2018 427 citations Katherine A. Donovan, Nathanael S. Gray et al. profile →
  17. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation
    2017 402 citations Eric S. Fischer, Richard A. Young et al. profile →
  18. CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer
    2015 347 citations Richard A. Young, Nathanael S. Gray et al. profile →
  19. A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader
    2017 330 citations Ellen Weisberg, Jaebong Jang et al. profile →
  20. A Quantitative Tissue-Specific Landscape of Protein Redox Regulation during Aging
    2020 260 citations David E. Heppner, Nathanael S. Gray et al. profile →
  21. Light-induced control of protein destruction by opto-PROTAC
    2020 226 citations Nathanael S. Gray et al. profile →
  22. Rewiring cancer drivers to activate apoptosis
    2023 89 citations Nathanael S. Gray et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nathanael S. Gray United States 104 30.5k 10.9k 5.0k 4.9k 4.0k 476 42.2k
Edward A. Sausville United States 92 19.3k 0.6× 11.7k 1.1× 2.7k 0.5× 2.8k 0.6× 3.0k 0.8× 329 30.9k
Neal Rosen United States 100 24.7k 0.8× 12.2k 1.1× 2.0k 0.4× 5.7k 1.2× 2.4k 0.6× 255 34.8k
Kevan M. Shokat United States 96 24.3k 0.8× 6.9k 0.6× 2.4k 0.5× 2.4k 0.5× 5.4k 1.4× 305 34.2k
Michael J. Eck United States 76 18.3k 0.6× 12.5k 1.1× 2.0k 0.4× 11.2k 2.3× 3.4k 0.9× 158 32.5k
Scott H. Kaufmann United States 95 25.8k 0.8× 11.9k 1.1× 1.2k 0.2× 1.8k 0.4× 2.8k 0.7× 406 36.2k
Donald Küfe United States 111 27.8k 0.9× 12.7k 1.2× 1.9k 0.4× 2.5k 0.5× 2.6k 0.7× 621 41.4k
Steven A. Carr United States 108 31.7k 1.0× 5.4k 0.5× 2.1k 0.4× 1.6k 0.3× 6.3k 1.6× 372 44.4k
James A. McCubrey United States 79 16.1k 0.5× 6.8k 0.6× 1.2k 0.2× 1.9k 0.4× 1.6k 0.4× 421 24.9k
Richard Jove United States 94 21.5k 0.7× 21.9k 2.0× 1.8k 0.4× 2.7k 0.5× 1.8k 0.4× 264 40.4k
Channing J. Der United States 111 36.2k 1.2× 12.7k 1.2× 1.2k 0.2× 2.3k 0.5× 10.6k 2.7× 406 48.3k

Countries citing papers authored by Nathanael S. Gray

Since Specialization
Citations

This map shows the geographic impact of Nathanael S. Gray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathanael S. Gray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathanael S. Gray more than expected).

Fields of papers citing papers by Nathanael S. Gray

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathanael S. Gray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathanael S. Gray. The network helps show where Nathanael S. Gray may publish in the future.

Co-authorship network of co-authors of Nathanael S. Gray

This figure shows the co-authorship network connecting the top 25 collaborators of Nathanael S. Gray. A scholar is included among the top collaborators of Nathanael S. Gray based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nathanael S. Gray. Nathanael S. Gray is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hassan, Muhammad Murtaza, Yen-Der Li, W Michelle, et al.. (2024). Exploration of the tunability of BRD4 degradation by DCAF16 trans-labelling covalent glues. European Journal of Medicinal Chemistry. 279. 116904–116904. 12 indexed citations
2.
Chen, Xi, Logan Fisher, Ian Mantel, et al.. (2024). Disrupting the RNA polymerase II transcription cycle through CDK7 inhibition ameliorates inflammatory arthritis. Science Translational Medicine. 16(774). eadq5091–eadq5091. 2 indexed citations
3.
Erickson, Emily C., Inchul You, Aurélien Dugourd, et al.. (2024). Multiomic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradation. Science Signaling. 17(825). eadf2670–eadf2670. 7 indexed citations
4.
Hatcher, John M., Adil R. Sarhan, Francesca Tonelli, et al.. (2023). Development of a highly potent and selective degrader of LRRK2. Bioorganic & Medicinal Chemistry Letters. 94. 129449–129449. 12 indexed citations
5.
Beyett, Tyler S., Ciric To, David E. Heppner, et al.. (2022). Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors. Nature Communications. 13(1). 2530–2530. 56 indexed citations
6.
Dall’Agnese, Alessandra, Julien Dubrulle, Hannah L. Johnson, et al.. (2021). Targeted brachyury degradation disrupts a highly specific autoregulatory program controlling chordoma cell identity. Cell Reports Medicine. 2(1). 100188–100188. 20 indexed citations
7.
Tang, Xin, Keji Li, Hao Wu, et al.. (2019). Pharmacological enhancement of KCC2 gene expression exerts therapeutic effects on human Rett syndrome neurons and Mecp2 mutant mice. Science Translational Medicine. 11(503). 89 indexed citations
8.
Jang, Jaebong, Jieun Son, Eunyoung Park, et al.. (2018). Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor. Angewandte Chemie International Edition. 57(36). 11629–11633. 23 indexed citations
9.
Liu, Yan, Yuyang Li, Xiaoen Wang, et al.. (2017). Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma. Cancer Research. 77(18). 5068–5076. 25 indexed citations
10.
Maxson, Julia E., Melissa L. Abel, Jinhua Wang, et al.. (2016). Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis. Cancer Research. 76(1). 127–138. 26 indexed citations
11.
Amato, Katherine, Shan Wang, Li Tan, et al.. (2016). EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. Cancer Research. 76(2). 305–318. 84 indexed citations
12.
Weisberg, Ellen, Atsushi Nonami, Chen Zhao, et al.. (2014). Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R. Clinical Cancer Research. 20(21). 5483–5495. 14 indexed citations
13.
Decker, Sarah, Juerg Schwaller, Nathanael S. Gray, et al.. (2014). PIM Kinases Are Essential for Chronic Lymphocytic Leukemia Cell Survival (PIM2/3) and CXCR4-Mediated Microenvironmental Interactions (PIM1). Molecular Cancer Therapeutics. 13(5). 1231–1245. 61 indexed citations
14.
Kang, Seong A., Michael E. Pacold, Christopher Cervantes, et al.. (2013). mTORC1 Phosphorylation Sites Encode Their Sensitivity to Starvation and Rapamycin. Science. 341(6144). 1236566–1236566. 3 indexed citations
15.
Beauchamp, Ellen M., Brittany A. Woods, Austin Dulak, et al.. (2013). Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by DDR2 Gatekeeper Mutation and NF1 Loss. Molecular Cancer Therapeutics. 13(2). 475–482. 44 indexed citations
16.
Liu, Qingsong, Jae Won Chang, Jinhua Wang, et al.. (2010). Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a Highly Potent, Selective Mammalian Target of Rapamycin (mTOR) Inhibitor for the Treatment of Cancer. DSpace@MIT (Massachusetts Institute of Technology). 11 indexed citations
17.
Sasaki, Takaaki, Katsuhiro Okuda, Wei Zheng, et al.. (2010). The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers. Cancer Research. 70(24). 10038–10043. 254 indexed citations
18.
McDermott, Ultan, Raju V. Pusapati, James G. Christensen, Nathanael S. Gray, & Jeff Settleman. (2010). Acquired Resistance of Non–Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency. Cancer Research. 70(4). 1625–1634. 129 indexed citations
19.
Weisberg, Ellen, Hwan Geun Choi, Rosemary Barrett, et al.. (2010). Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors. Molecular Cancer Therapeutics. 9(9). 2468–2477. 12 indexed citations
20.
Ding, Sheng, Tom Wu, Achim Brinker, et al.. (2003). Synthetic small molecules that control stem cell fate. Proceedings of the National Academy of Sciences. 100(13). 7632–7637. 306 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Edward A. Sausville Breakdown of academic impact, for papers by Neal Rosen Breakdown of academic impact, for papers by Kevan M. Shokat Breakdown of academic impact, for papers by Michael J. Eck Breakdown of academic impact, for papers by Scott H. Kaufmann Breakdown of academic impact, for papers by Donald Küfe Breakdown of academic impact, for papers by Steven A. Carr Breakdown of academic impact, for papers by James A. McCubrey Breakdown of academic impact, for papers by Richard Jove Breakdown of academic impact, for papers by Channing J. Der
Rankless by CCL
2026